That suspicion has been fueled by a striking clinical observation. Reduced GLO1 expression has been reported both in experimental models of metabolic dysfunction-associated fatty liver disease, or MAFLD, and in liver biopsies from patients with the condition. MAFLD, driven by excessive fat storage in the liver, is estimated to affect roughly 24 percent of the United States population and is present in more than 70 percent of patients with type 2 diabetes, making it one of the most common and consequential comorbidities of the modern obesity pandemic. Sustained consumption of high-carbohydrate diets, particularly those rich in fructose, is a major driving factor in the pathogenesis of both obesity and MAFLD, and fructose-containing foods are capable of inducing insulin resistance in humans and metabolic syndrome in mice. Yet despite the clear association between diminished GLO1 and fatty liver disease, a fundamental question remained unanswered: is the loss of GLO1 a cause of the disease, or merely a compensatory response to it?

A new study published in Physiological Reports by a team at the University of Arizona set out to resolve this question directly. Rather than merely observing correlations, the researchers generated whole-body Glo1 knockout mice using CRISPR-SpCas9 genome editing in the C57Bl/6NN strain, targeting exon 3 of the Glo1 gene with guide RNAs to produce frameshift deletions through non-homologous end joining. They then challenged these mice, alongside wild-type controls, with sixteen weeks of a high-fat, high-sucrose diet containing 36 percent fat and 30 percent sucrose, a regimen well documented to induce fatty liver disease and impair glucose tolerance. The team’s initial hypothesis was straightforward: if reduced GLO1 expression contributes to MAFLD, then deleting the gene should exacerbate metabolic dysfunction by increasing MGO-mediated stress. What they found instead was a surprise that reshapes how the field should think about the glyoxalase system.

Contrary to expectations, the knockout mice were substantially protected from hepatic fat accumulation. When wild-type mice consumed the obesogenic diet, they developed substantial hepatic steatosis, with triglycerides building up in the liver as expected. In the Glo1-deficient mice fed the same diet, this triglyceride accumulation was significantly blunted. The protection was specific to the liver: adipose tissue biology was largely unaffected, with no significant differences in adipocyte size, epididymal white adipose tissue mass, or markers of fat tissue injury between genotypes under the high-fat, high-sucrose conditions. Serum triglycerides and beta-hydroxybutyrate, a readout of fatty acid oxidation, varied only with diet and not with genotype, suggesting that the hepatic phenotype was not secondary to altered fat export or whole-body fat burning. The findings point toward a previously unrecognized role for GLO1 in directly regulating hepatic lipid metabolism, positioning the enzyme as an unexpected participant in the biology of fatty liver rather than a passive bystander.

But the metabolic ledger did not balance cleanly. While the knockout mice enjoyed relative protection from fatty liver, their systemic glucose handling deteriorated in a diet-dependent manner. Fasting blood glucose was significantly elevated in high-fat, high-sucrose-fed knockout mice compared with their wild-type counterparts. Oral glucose tolerance testing revealed a significant reduction in the ability of knockout mice to clear systemic glucose when compared with chow-fed controls, and although the difference between the two genotypes on the obesogenic diet did not reach statistical significance in the raw tolerance curves, a deeper analysis told a more troubling story. The constant of glucose decay, calculated from insulin tolerance testing as the rate of glucose disappearance, revealed a significant reduction in insulin responsiveness specifically in the high-fat, high-sucrose-fed knockout mice. Notably, serum insulin levels and hepatic insulin signaling, assessed through phosphorylation of the insulin receptor and AKT, showed no significant differences, indicating that the glucose defect operates independently of measurable changes in insulin activity.

To understand the biochemistry underlying these divergent phenotypes, the researchers turned to sensitive mass spectrometry-based quantification of MGO and its downstream molecular footprints. Free hepatic MGO was not significantly elevated in any treatment group, and the product of GLO1 activity, lactoylglutathione, was significantly reduced in the knockout mice, consistent with the loss of enzyme function. A complicating factor emerged, however: the high-fat, high-sucrose diet produced a marked reduction in hepatic glutathione regardless of genotype, and because glutathione is required for GLO1 activity, the reduction in lactoylglutathione may partly reflect this glutathione depletion. When the team examined MGO-derived post-translational modifications on proteins, the results were equally nuanced. Levels of MGO-hydroimidazolone 1, a signature MGO-derived arginine modification, were not significantly affected by diet or genotype, while carboxyethylarginine was elevated in chow-fed knockout mice. These data contradict previous reports indicating dramatic elevations in MGO-derived modifications under diet-induced metabolic stress, and they suggest that steady-state MGO biology in vivo is more buffered than cell culture experiments would predict.

The study also delivered a decisive verdict on a long-standing controversy in diabetes research. Earlier work using short hairpin RNA to knock down Glo1 reported that reduced GLO1 activity could spontaneously generate pathologies resembling diabetic nephropathy in non-diabetic mice, fueling the idea that GLO1 loss is a primary driver of diabetic kidney disease. The Arizona team therefore reasoned that sixteen weeks of high-fat, high-sucrose feeding would exacerbate kidney injury in their knockout animals. Instead, they found no evidence of renal pathology attributable to GLO1 loss. Kidney glycogen accumulated with the obesogenic diet but was unaffected by genotype, serum urea and creatinine were unchanged across all cohorts, and renal levels of MGO-hydroimidazolone 1, carboxyethylarginine, and 3-nitrotyrosine, a modification associated with oxidative stress, showed no significant differences. These findings independently confirm earlier reports from a separate group that complete genetic deletion of Glo1 fails to reproduce the diabetic kidney phenotype seen with knockdown approaches, and they collectively indicate that loss of GLO1 alone is insufficient to drive diabetic nephropathy.

Why might deleting a detoxification enzyme protect the liver while harming glucose control? The authors offer several mechanistic possibilities grounded in their own prior work. In cultured fibroblasts, they previously showed that loss of GLO1 reduces glucose uptake and glycolytic flux, and that Glo1-deficient cells fail to differentiate into mature adipocytes. If a similar reduction in glycolytic flux occurs in the livers of knockout mice in vivo, it would limit the substrate available for MGO generation, potentially explaining why free MGO and MGO-derived modifications remain largely unchanged despite the absence of the primary detoxification enzyme. Reduced glycolytic flux could also directly limit de novo lipogenesis, the pathway by which the liver converts excess carbohydrate into fat, providing a plausible mechanism for the blunted hepatic triglyceride accumulation. Meanwhile, the concept that MGO is not simply a toxin but a concentration-dependent metabolic signal is gaining traction: modest elevations of MGO have been reported to be protective in cardiac ischemia-reperfusion injury and even stimulatory for tumor growth, while only cytotoxic concentrations far exceeding those measured in vivo cause cell death.

The authors are careful to note the limitations of their work. The dietary intervention was terminated at sixteen weeks, a timepoint at which significant hepatic steatosis is evident but more advanced features of MAFLD, such as frank inflammation and fibrosis, have not yet developed. Whether GLO1 influences disease progression at later stages, including the transition to metabolic dysfunction-associated steatohepatitis, remains unknown and is a focus of ongoing investigation. The study also focused on male mice, leaving potential sex differences unexplored, and it did not evaluate alternative MGO detoxification pathways, such as the aldehyde dehydrogenases and aldose reductase, which are thought to play secondary roles but could become important under chronic metabolic stress. Samples for insulin signaling analysis were collected from fed rather than fasted mice, so the effect of GLO1 on glucose-stimulated insulin secretion could not be assessed.

Even with these caveats, the study carries a clear and provocative message: hepatic lipid accumulation and systemic glycemic control are mechanistically distinct in the absence of GLO1, and the glyoxalase system sits at an unexpected crossroads between the two. For a field that has largely treated MGO as a toxic metabolic accident and GLO1 as a straightforward protective enzyme, the demonstration that complete GLO1 loss limits fatty liver while impairing glucose handling in obese male mice demands a more sophisticated view. Future investigations aimed at deciphering the tissue-specific roles of GLO1 in whole-body glucose tolerance and lipid metabolism may reveal whether the glyoxalase cycle, long relegated to the footnotes of biochemistry textbooks, holds therapeutic potential for one of the most common liver diseases of our time.

Subject of Research: The role of glyoxalase 1 in obesity-associated fatty liver disease, glucose homeostasis, and kidney health in mice.

Article Title: Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice

Article References: Hoffman, E. A., Phoebe, A. M., Trujillo, M. N., Zhang, W. C., Jennings, E. Q., Farrera, D. O., Orlicky, D. J., Rutt, L. N., McCullough, R. L., Huacachino, A. A., Marcinkiewicz, M. M., Snyder, N. W., Bruner, K. R., Payan, K. B., Martinez, D. J. F., Stern, J. H., & Galligan, J. J. (2026). Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice. Physiological Reports, 14(17), Article e71106. https://doi.org/10.14814/phy2.71106

Image Credits: AI Generated

DOI: 10.14814/phy2.71106

Keywords: glyoxalase 1, methylglyoxal, fatty liver disease, MAFLD, glucose tolerance, hepatic triglycerides, glyoxalase cycle, high-fat high-sucrose diet, diabetic nephropathy, glycolysis, post-translational modifications, knockout mice

The scale of the blind spot is considerable. Population studies and meta-analyses cited by the group show that MASLD increases the risk of fatal and non-fatal cardiovascular events, new-onset heart failure, and atrial fibrillation. One recent meta-analysis of around 11 million individuals linked fatty liver disease to a significantly elevated risk of incident heart failure, and biopsy-proven cohorts have revealed that incident heart failure is both common and frequently missed in these patients. The group describes a global cardiovascular–liver–metabolic ‘syndemic’, in which shared risk factors such as obesity, type 2 diabetes and dyslipidaemia drive parallel epidemics of liver fibrosis and cardiovascular disease. When each speciality manages only its own organ, patients fall through the gaps, interventions arrive late, and outcomes suffer on both fronts.

At the mechanistic level, the liver and the heart are locked in bidirectional dialogue. The steatotic liver acts as an endocrine and inflammatory organ, exporting excess very-low-density lipoproteins, pro-inflammatory cytokines and other mediators that promote endothelial dysfunction, atherosclerosis and myocardial remodelling. Hepatic insulin resistance aggravates systemic metabolic dysfunction, while emerging proteomic work suggests that distinct organ-damage signatures can flag MASLD patients at risk of systemic complications before overt disease develops. Conversely, cardiac dysfunction feeds back on the liver: elevated central venous pressure in heart failure congests the hepatic circulation, and experimental evidence shows that myocardial infarction can accelerate steatohepatitis by triggering immunoinflammatory responses. Recent research also suggests that low-to-moderate alcohol intake and hypertension both amplify fibrosis progression in MASLD, tightening the links between metabolic, hepatic and cardiac trajectories.

A central tenet of the recommendation is that liver fibrosis, rather than simple steatosis, is the pivotal risk stratifier. Fat in the liver alone carries a more modest prognostic signal; the accumulation of fibrous scar tissue is what tracks with hepatic decompensation, cardiovascular events and mortality. The authors therefore propose that the degree of fibrosis should guide not only hepatological monitoring but also cardiovascular risk assessment, effectively serving as a shared currency between the two disciplines. Data from the global burden of disease project and longitudinal cohort analyses indicate that fibrosis stage predicts clinical events across the MASLD spectrum, including in so-called lean individuals, and that patients with coexisting cardiovascular–kidney–metabolic syndrome progress to advanced fibrosis and liver-related events more rapidly.

To operationalise this insight, the paper lays out a stepwise screening algorithm designed for real-world efficiency. First-line assessment uses the fibrosis-4 index, a simple calculation from age, aminotransferases, platelet count and aspartate aminotransferase that can be computed in any clinic. Patients flagged by this inexpensive test proceed to vibration-controlled transient elastography, a non-invasive ultrasound-based measurement of liver stiffness, and those with concerning results are referred for specialist evaluation. This cascade, the authors argue, enables identification of clinically significant fibrosis and high-risk metabolic phenotypes without resorting to liver biopsy in most patients, and it aligns with recent European screening studies that found previously unrecognised liver fibrosis to be common in the general population. The same non-invasive tools can be deployed longitudinally, since changes in stiffness and fibrosis markers over time carry prognostic information for both organ systems.

On the therapeutic front, the framework recommends pairing intensive lifestyle intervention with cardiometabolic drug classes that deliver dual liver and cardiovascular benefits. Glucagon-like peptide 1 receptor agonists have now demonstrated histological improvement in steatohepatitis in phase 3 trials of semaglutide and tirzepatide, alongside established reductions in major adverse cardiovascular events, heart failure hospitalisation and, for tirzepatide, benefit in obesity-related heart failure with preserved ejection fraction. Sodium–glucose cotransporter 2 inhibitors similarly combine cardiovascular and renal protection with emerging evidence of reduced liver-related events and mortality in patients with MASH cirrhosis. Meanwhile, resmetirom, the first approved liver-directed therapy for MASH with moderate to advanced fibrosis, addresses the hepatic side of the equation and has gained regulatory approval in both the United States and Europe. Statins, the authors add, remain underused in MASLD despite evidence of multisystem benefit and reassuring hepatic safety.

The recommendation does not stop at individual drugs; it embeds them within a structured metabolic care framework that treats the patient as a cardiometabolic whole. Data-driven cluster analyses and polygenic risk scores now identify biologically distinct MASLD subtypes, some predisposed to severe fibrosis and others to cardiometabolic complications, offering a route to precision-matched therapy. The authors argue that cardiovascular risk calculators such as SCORE2 and the American Heart Association’s PREVENT equations should be complemented by markers that capture the MASLD-specific burden, including high-sensitivity C-reactive protein, lipoprotein(a), inflammation indices and non-invasive fibrosis measures. They also stress aggressive management of hypertension, diabetes and dyslipidaemia, careful attention to alcohol consumption, and recognition that cardiovascular events themselves accelerate liver disease progression.

Implementation, the group acknowledges, is the hardest part. Quality-standards audits in the United Kingdom have documented wide variation in fatty liver disease care delivery, and therapeutic inertia remains endemic in cardiovascular prevention. The paper therefore proposes concrete pathways: bidirectional referral arrangements in which cardiologists screen for MASLD using FIB-4 and hepatologists routinely assess cardiovascular risk; shared care clinics and multidisciplinary teams; embedded non-invasive liver measures in both cardiology and hepatology workflows; and co-management protocols that specify who monitors what, and when. Clinical trials, they contend, should likewise embed dual hepatic and cardiovascular endpoints, a roadmap recently elaborated for multiorgan trial design spanning the MASLD–MASH–cardiovascular–kidney–metabolic spectrum. Without such integration, the benefits of newly available therapies risk accruing to the minority of patients who already navigate both specialities successfully.

The paper’s broader message is a reframing of MASLD itself: from an incidental imaging finding, or a condition waiting for cirrhosis, to a systemic metabolic disease whose most lethal complication is often cardiac. With global projections suggesting the MASLD burden will continue to climb through 2050, and cause-specific mortality data showing cardiovascular death outpacing liver-related death in these patients, the stakes of getting co-management right are high. The authors, whose work is supported by the CHAIN Consortium, position their expert recommendation as a practical bridge between cardiology and hepatology, one built on existing tools rather than speculative technology. If adopted, the framework could convert a fragmented two-organ problem into a single, coherent cardiometabolic care pathway, closing screening gaps, sequencing therapies by fibrosis stage and cardiovascular risk, and ultimately reducing the twin burdens of heart disease and liver failure in one of the world’s most common chronic conditions.

The shift in terminology itself reflects the evolving understanding of the disease. The multisociety Delphi consensus that introduced the MASLD nomenclature in 2023 deliberately replaced older terms to emphasise metabolic dysfunction as the unifying mechanism, and to allow coexistence with other hepatic conditions such as alcohol-associated liver disease. This reframing matters clinically, because the metabolic cluster that defines MASLD overlaps almost completely with the risk factors tracked by cardiovascular prevention guidelines, making the liver a natural target organ for cardiometabolic screening programmes.

Epidemiological data underpinning the recommendation are substantial. The Global Burden of Disease Study 2023 analysis projected continued growth in MASLD prevalence through mid-century, and systematic reviews have documented that hepatic and extrahepatic cancers, cardiovascular events and chronic kidney disease collectively account for a large share of adverse outcomes, with liver-related mortality no longer dominating the natural history except in advanced fibrosis. This changing pattern of mortality is precisely why the authors argue that risk stratification must serve two organ systems simultaneously.

The screening tools proposed also carry caveats worth noting. The fibrosis-4 index performs well at ruling out advanced fibrosis but has limited specificity, particularly in middle-aged patients with obesity or diabetes, where false positives are common and can drive unnecessary referrals. Vibration-controlled transient elastography offers better discrimination but can be unreliable in obesity and in acute hepatic inflammation, and access remains uneven across health systems. The stepwise algorithm therefore functions best as a triage instrument, reserving liver biopsy for indeterminate cases where the result would change management.

On the pharmacological side, the dual-benefit argument is supported by an expanding evidence base. Incretin-based therapies act on hepatic, adipose and central nervous system pathways that influence appetite, insulin sensitivity and hepatic fat flux, while sodium–glucose cotransporter 2 inhibitors shift myocardial metabolism and reduce cardiac congestion. Resmetirom, a selective thyroid hormone receptor-beta agonist, targets hepatic mitochondrial function and fat oxidation, complementing rather than replacing systemic metabolic therapy. The authors emphasise that sequencing these agents according to fibrosis stage and cardiovascular risk profile remains an open question that only trials with dual endpoints can resolve, reinforcing their call for co-management pathways embedded in routine practice.

Subject of Research: Heart–liver co-management and multidisciplinary cardiometabolic care in metabolic dysfunction-associated steatotic liver disease (MASLD)

Article Title: Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework

Article References: Zhou, X.-D., Jeong, S., Chen, Q.-F., Targher, G., Byrne, C. D., Chew, N. W. S., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., Stefan, N., Sperling, L. S., Luu, H. N., Fudim, M., Loomba, R., & Zheng, M.-H. (2026). Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01255-z

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01255-z

Keywords: MASLD, cardiovascular disease, liver fibrosis, heart–liver co-management, FIB-4, transient elastography, GLP-1 receptor agonists, SGLT2 inhibitors, resmetirom, cardiometabolic syndrome, risk stratification, multidisciplinary care

MASLD is no longer a niche concern. It encompasses a spectrum running from simple hepatic steatosis to the inflammatory, fibrotic condition known as metabolic dysfunction-associated steatohepatitis, and it is tightly coupled to obesity and type 2 diabetes. Treatment options remain frustratingly thin. The recent approval of resmetirom, a thyroid hormone receptor-beta agonist that became the first FDA-approved medication for nonalcoholic steatohepatitis, marked a genuine milestone, but clinicians still lack cheap, safe, preventive strategies for the vast population of patients with early disease. That gap has pushed researchers toward nutraceuticals—food-derived compounds with drug-like activity—and toward the gut microbiome as a therapeutic target in its own right.

The gut–liver axis sits at the center of the new review’s argument. The liver receives the portal blood supply directly from the intestine, along with everything the gut microbes produce: short-chain fatty acids, bile acid derivatives, trimethylamine N-oxide, indole compounds, endotoxins, and ethanol made by bacteria themselves. When the microbial community falls into dysbiosis—a state that clinical studies have repeatedly linked to the severity of fatty liver disease—the balance of these metabolites tips. Barrier function in the intestine weakens, bacterial lipopolysaccharide leaks into circulation, hepatic inflammation and oxidative stress escalate, and hepatocytes accumulate fat. Some evidence even implicates high-alcohol-producing Klebsiella pneumoniae in driving fatty liver in non-drinkers, underscoring how directly microbial chemistry can become hepatic pathology.

What makes marine polysaccharides different from the plant fibers already celebrated in nutrition? The authors emphasize structural chemistry. Land-based fibers are built largely from neutral sugars, whereas marine polysaccharides—fucoidans from brown seaweeds, carrageenans from red algae, ulvans from green algae, agars and porphyrans from Porphyra, alginates from kelp, chitosan from crustacean shells, and sulfated glycans from sea cucumbers—carry sulfate groups and uronic acids, form complex glycosidic linkages, adopt diverse conformations, and span broad molecular-weight distributions. Those features mean that human enzymes cannot digest them, but specific gut bacteria can, using elaborate carbohydrate-active enzyme systems called polysaccharide utilization loci. The result is selective feeding: particular structures recruit particular microbial taxa, shifting community composition in reproducible, mechanism-linked ways.

Human populations provide a striking natural experiment. Japanese individuals harbor gut bacteria that acquired genes for digesting marine sulfated polysaccharides from marine Bacteroides via horizontal gene transfer, a discovery that revealed how the microbiome can expand its metabolic repertoire when the diet supplies novel glycans. Subsequent genomic work identified multiple independent transfer events that seeded seaweed-digestion genes into human gut bacteria. This capacity for adaptation is precisely what marine polysaccharide therapy hopes to exploit: by supplying glycans that only beneficial consumers can process, these compounds act as targeted prebiotics, enriching organisms such as Lactobacillus, Akkermansia muciniphila, and beneficial Bacteroides species while suppressing inflammatory lineages.

The downstream metabolic consequences are where the review gets technically ambitious. Fermentation of marine polysaccharides yields short-chain fatty acids—acetate, propionate, and butyrate—which nourish colonocytes, strengthen tight junctions, and engage G-protein-coupled receptors that regulate glucose homeostasis and appetite. Simultaneously, polysaccharide-driven changes in bile acid metabolism alter signaling through the nuclear receptor FXR and the membrane receptor TGR5, pathways now recognized as central to hepatic lipid handling, energy expenditure, and inflammation. At the hepatocyte level, marine polysaccharides and their oligosaccharide fragments activate AMPK and PPARα, the master switches of fatty acid oxidation, and engage the Nrf2 antioxidant program, directly countering the lipid accumulation and oxidative stress that define steatohepatitis.

Preclinical evidence illustrates the breadth of this approach. Fucoidan from Sargassum fusiforme alleviated high-fat diet-induced obesity and insulin resistance while improving the gut microbiota profile and hepatic oxidative stress. Alginate oligosaccharides relieved insulin resistance and fatty liver in mice through microbiota-mediated bile acid regulation. Iota-carrageenan tetrasaccharide reduced liver lipid accumulation via the bile acid–FXR–SHP/PXR pathway, and chitosan oligosaccharides attenuated steatosis, inflammation, and oxidative stress in diet-induced obese mice. Sea cucumber fucosylated chondroitin sulfate modified gut microbiota to prevent obesity, and oyster polysaccharide ameliorated hepatic oxidative stress through the bile acid–FXR–AMPKα axis. Porphyran from discolored nori prevented metabolic syndrome through a microbiota–bile acid–ceramide pathway, while ulvan oligosaccharides regulated lipid metabolism in high-fat diet-fed animals.

Clinical data, though still early, are encouraging. A randomized, double-blinded, placebo-controlled trial found that chitosan supplementation improved liver function, hepatic steatosis predictors, and metabolic indicators in adults with non-alcoholic fatty liver disease. Chitooligosaccharides rebalanced gut microorganisms and their metabolites in NAFLD patients, and Icelandic trial data showed that chitosan supplementation favorably altered the gut microbiota in healthy women. A fucoidan extract improved insulin resistance and cardiometabolic markers in obese, nondiabetic subjects in a randomized controlled trial, and fucoidan has also demonstrated clinical efficacy as an adjunct in Helicobacter pylori eradication, hinting at broad microbiome-modulating potential. Trials combining Laminaria japonica with probiotics improved intestinal microbiota in human volunteers, and fecal microbiota transplantation protocols now being tested in steatohepatitis underscore how central microbial manipulation has become to the field.

The review is candid about the obstacles between laboratory promise and clinical reality. Marine polysaccharides are structurally heterogeneous, and batch-to-batch variation in sulfation pattern, molecular weight, and monosaccharide composition makes standardization difficult—yet those same variables appear to determine biological activity, as shown by recent synthetic fucoidan libraries that enabled systematic structure–function comparisons. Safety questions also persist, particularly for carrageenan, a widely used food additive whose degraded forms have been associated with intestinal inflammation in some animal and human studies, even as food-grade material appears benign in others; clarifying this controversy is essential for consumer confidence. Contaminant burdens in macroalgae, including arsenic, cadmium, lead, and mercury, require careful regulatory alignment between producing and consuming regions. Dosing, bioavailability, and long-term effects remain underexplored.

Nevertheless, the authors position marine polysaccharides as uniquely advantaged relative to terrestrial fibers: their unusual chemistries reach microbial niches that common fibers cannot, and their pleiotropic effects—spanning short-chain fatty acid production, bile acid signaling, barrier protection, endocrine modulation, and direct hepatic pathway activation—map precisely onto the multi-organ pathophysiology of MASLD. As sequencing technologies make it possible to identify exactly which bacteria consume which glycans, and as controlled synthesis enables reproducible materials, the field is converging on a rational design framework: engineer polysaccharide structures to recruit defined beneficial communities and thereby steer the gut–liver axis away from disease. If clinical trials confirm the early human signals, the humble slime of the seashore may prove to be one of the most practical liver medicines of the coming decade—harvested not from a pharmaceutical plant, but from the wrack line.

The scale of the unmet need gives this research agenda its urgency. Population studies suggest that roughly a third of adults in many industrialized countries carry hepatic steatosis, with prevalence climbing in children and adolescents, yet most affected individuals are identified only incidentally or through rising cardiometabolic risk factors. Because early-stage disease is largely asymptomatic, an intervention that could be delivered safely as a dietary supplement—and taken for years—would address a far larger population than any prescription drug realistically can.

The prebiotic framing deserves careful attention. Classic prebiotics such as inulin and fructooligosaccharides are fermented broadly by common saccharolytic organisms, which can limit how precisely a community can be steered. Sulfated marine glycans, by contrast, demand specialized enzyme machinery, so only microbes equipped with the appropriate sulfatases and carbohydrate-active enzymes can access them. This substrate specificity is the theoretical basis for precision microbiome editing through diet, and it explains why the authors treat structural chemistry rather than fiber content as the decisive design variable.

Molecular weight emerges as a recurring theme in the preclinical literature. High-molecular-weight polymers are often poorly soluble and difficult for microbes to process, while controlled depolymerization into oligosaccharides frequently enhances water solubility, bioactivity, and fermentability. Several of the most striking animal results cited in the review involve oligosaccharide fragments rather than intact polymers, suggesting that processing technology—enzymatic degradation, controlled hydrolysis, or even synthetic chemistry—will be as important as source selection for future products.

Practical considerations also favor the field. Many marine polysaccharides already hold food additive or generally recognized as safe status in major jurisdictions, and industrial supply chains for carrageenan, alginate, and agar are mature, which could shorten the path from bench to consumer. Seasonal and geographic variation in seaweed composition remains a genuine hurdle, but cultivation of defined macroalgal strains under controlled conditions offers a route to more consistent raw material than wild harvest alone.

What remains most persuasive is the convergence of mechanisms: microbial selection, metabolite generation, barrier reinforcement, and direct hepatic signaling all point in the same direction. Few nutraceutical candidates offer that degree of mechanistic coherence, and few target a disease with such a large and growing affected population.

Subject of Research: Marine polysaccharides as nutraceutical modulators of the gut microbiome and gut–liver axis in metabolic dysfunction-associated steatotic liver disease

Article Title: Marine polysaccharides: promising nutraceuticals for metabolic dysfunction-associated steatotic liver disease as unique and potent modulator of gut microbiome

Article References: Pan, Y., Zhang, R., & Chen, Y. (2026). Marine polysaccharides: promising nutraceuticals for metabolic dysfunction-associated steatotic liver disease as unique and potent modulator of gut microbiome. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02283-w

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02283-w

Keywords: marine polysaccharides, MASLD, gut microbiome, gut–liver axis, fucoidan, carrageenan, ulvan, chitosan, short-chain fatty acids, bile acid signaling, nutraceuticals, fatty liver disease

MASLD, formerly known as non-alcoholic fatty liver disease, affects a substantial and growing proportion of the global population, closely tracking the worldwide rise in obesity, type 2 diabetes, and metabolic syndrome. In its early and middle stages, the condition is still reversible with timely clinical intervention. Left unmanaged, however, it can progress to inflammation, fibrosis, cirrhosis, and ultimately liver failure or cancer. Precisely because the window for intervention is widest early in the disease, identifying new molecular targets has become a major priority for hepatology researchers. The new study, led by Tiansu Lv, Hongshan Dai, Shihu Zhang, and colleagues under the co-corresponding authorship of Feng Zhang and Xiqiao Zhou at Jiangsu Province Hospital of Chinese Medicine and collaborating institutions in Nanjing, offers one of the most detailed multi-scale portraits to date of what goes wrong inside the liver microenvironment during MASLD—and introduces an entirely new cell type into the picture.

What makes the study technically striking is the layered, multi-platform strategy the team employed. Rather than relying on a single analytical technique, the researchers combined high-dimensional single-cell immunophenotyping with mass spectrometry–based proteomics, phosphoproteomics, and spatial proteomics, followed by mechanistic validation in cell models. The first stage used cytometry by time of flight, or CyTOF, a technology that tags cells with heavy-metal-conjugated antibodies and measures dozens of protein markers simultaneously in each individual cell by mass spectrometry. This allowed the team to map the immune landscape of the MASLD liver in unprecedented detail, distinguishing cell populations that conventional flow cytometry would collapse into indistinguishable groups.

The CyTOF analysis produced a clear and consequential signal: myeloid-derived cells—the broad family of innate immune cells that includes monocytes, macrophages, and dendritic cells—were significantly expanded in MASLD liver tissue. That expansion made the myeloid compartment the obvious next target. The team therefore sorted these key cell populations and subjected them to liquid chromatography–tandem mass spectrometry (LC–MS/MS) with label-free quantification, probing both the total proteome and the phosphoproteome—the complete set of phosphorylated proteins that reveals which signaling pathways are switched on or off inside the cells. Phosphoproteomics is particularly powerful here because phosphorylation events are the molecular currency of cellular communication; mapping them provides a direct readout of pathway activity rather than mere protein abundance.

The proteomic and phosphoproteomic analyses converged on a surprising culprit: amino acid metabolism. Two metabolic pathways emerged as severely impaired in the myeloid cells of MASLD patients. The first was the glycine metabolic pathway, regulated by the enzyme alanine-glyoxylate aminotransferase 2, or AGXT2. The second was the proline metabolic pathway, regulated by pyrroline-5-carboxylate reductase 3, or PYCR3, an enzyme that catalyzes the final step in proline biosynthesis, converting Δ1-pyrroline-5-carboxylate into proline. Glycine and proline may sound like obscure biochemical players, but both are deeply intertwined with cellular health: glycine feeds glutathione synthesis, the cell’s master antioxidant defense, while proline is essential for protein synthesis, redox balance, and—critically for the liver—collagen production by fibrotic cells.

To find out where in the diseased liver these metabolic defects were concentrated, the researchers turned to imaging mass cytometry, or IMC. This spatial proteomics technique combines the multiplexing power of mass cytometry with high-resolution tissue imaging: tissue sections, including formalin-fixed paraffin-embedded clinical samples, are stained with panels of metal-tagged antibodies, and a laser ablates the tissue pixel by pixel while a mass spectrometer records the metal signal at each position. The result is a map showing, at single-cell resolution, which cells express which dozens of proteins—and, crucially, which cells sit next to which. Applying IMC to liver biopsies from MASLD patients and healthy controls, the team homed in on the two metabolic enzymes and made their central discovery: a subset of macrophages that were negative for both AGXT2 and PYCR3.

These AGXT2−PYCR3− macrophages were significantly enriched in MASLD livers compared with healthy tissue. But abundance alone was not the striking part. The spatial analysis showed that these cells exhibited high colocalization with inflammatory cells and fibrotic cells—they were physically clustered in the exact neighborhoods where inflammation and scarring unfold. Within the macrophage compartment, the team compared different dysregulated subsets and found that the M2-type dysregulated cluster (designated M2-C1), which encompasses the AGXT2−PYCR3− population, displayed even stronger pro-inflammatory and pro-fibrotic potential than the dysregulated M1 subset (M1-C3). This is notable because M2 macrophages are classically considered the “reparative,” anti-inflammatory arm of the macrophage family; the finding that a dysregulated M2-like subset could be more inflammatory and fibrogenic than its M1 counterpart underscores how profoundly amino acid metabolic failure rewires immune cell identity.

To move beyond correlation, the researchers built in vitro models using both human THP-1-derived macrophages and murine RAW264.7 macrophages, in which AGXT2 and PYCR3 expression was knocked down using siRNA and shRNA approaches, recapitulating the metabolic defect seen in patient tissue. The results were unambiguous. Macrophages lacking AGXT2 and PYCR3 showed enhanced proliferation and migration—behaviors consistent with aggressive tissue infiltration. They secreted higher levels of inflammatory cytokines and chemokines, the signaling molecules that recruit further immune cells to sites of damage. They also released elevated amounts of classic fibrotic proteins and exerted a strong inductive effect on hepatic fibrotic cells, essentially coaching other cells in the liver to adopt a scar-producing phenotype. A key biochemical clue accompanied these observations: intracellular glutathione, or GSH, was downregulated in the defective macrophages, linking the metabolic lesion to a collapse in antioxidant capacity and the oxidative stress that drives inflammation.

The mechanistic dissection revealed which signaling circuits were responsible. The heightened inflammatory output traced to activation of the NF-κB pathway and the MAPK/AP-1 pathway—two of the most important transcriptional programs governing inflammatory gene expression. The pro-fibrotic behavior, meanwhile, was driven by phosphorylation of SMAD3 at threonine 8 within the TGFβ signaling axis, the canonical pathway that instructs cells to produce collagen and other extracellular matrix components. In other words, losing two amino acid metabolic enzymes in macrophages was sufficient to switch on the master regulators of both inflammation and fibrosis—the twin engines of MASLD progression.

Perhaps the most clinically tantalizing result came next. When the researchers supplemented the defective macrophage cultures with the corresponding amino acids—restoring the glycine and proline supply that the broken metabolic pathways could no longer adequately generate—the aberrant phenotypes were effectively rescued. Proliferation, migration, cytokine secretion, and fibrotic signaling all receded, accompanied by reversal of the abnormal NF-κB, MAPK/AP-1, and p-SMAD3/TGFβ pathway activation. While amino acid supplementation in a culture dish is a very long way from a therapy in a patient—the study’s in vitro findings will require extensive validation, including animal studies and ultimately clinical trials—the result establishes an initial, mechanistic link between amino acid metabolism and early-to-middle-stage MASLD, and it suggests a conceptual framework in which metabolic support of immune cells might blunt disease progression.

The work also carries methodological significance for the field. By integrating CyTOF, quantitative proteomics, phosphoproteomics, and IMC within a single study design, the researchers demonstrated a pipeline that moves fluidly from unbiased discovery of cellular changes to spatial localization in actual patient tissue to mechanistic confirmation in controlled models. This end-to-end approach addresses a persistent weakness in single-cell biology, where discoveries made in dissociated cell suspensions often fail to be anchored in their true tissue context. Here, the spatial data were essential: without IMC, the intimate physical association between AGXT2−PYCR3− macrophages, inflammatory cells, and fibrotic cells would have remained invisible.

The study, conducted with ethical approval from Jiangsu Province Hospital of Chinese Medicine and published open access, was funded by the National Natural Science Foundation of China and provincial research programs. The authors note that the term MASLD is used throughout to avoid stigmatizing patients, and that no animal experiments were involved in the research. As MASLD prevalence continues to climb worldwide, the identification of AGXT2−PYCR3− macrophages offers researchers a new cellular target, a new biomarker candidate, and a fresh biochemical hypothesis—all pointing toward the possibility that the road to liver fibrosis runs, at least in part, through broken amino acid metabolism in the immune cells that patrol the hepatic frontier.

MASLD, previously known as non-alcoholic fatty liver disease, has become the most prevalent chronic liver condition globally, with an estimated worldwide prevalence of approximately 38 percent based on recent systematic reviews. It ranges from simple fat accumulation to inflammation and fibrosis and can progress to cirrhosis and hepatocellular carcinoma. There are few approved pharmacological treatments, and understanding the underlying molecular drivers is a priority for researchers. Mitochondrial dysfunction has long been recognized as a central feature of MASLD. Mitochondria are the energy factories of the hepatocyte, and when they fail, fatty acids accumulate inside the cell and inflammatory damage follows. Mitophagy — the selective autophagic degradation of damaged mitochondria — is the cell’s quality control system for keeping its mitochondrial network healthy. Earlier work from other groups has shown that restoring mitophagy, for instance with quercetin or cyanidin-3-O-glucoside, can improve fatty liver disease in animal models, and that impaired mitophagy is a mechanistic biomarker in patients with the disease. But the regulatory circuits that shut mitophagy down during MASLD development have remained incompletely mapped.

The new study, led by Mei Long of the Department of Rheumatology and Immunology at the First Affiliated Hospital of Hengyang Medical School, University of South China, together with Kewei Tan of the No. 922 Hospital of the People’s Liberation Army Joint Logistics Support Force and Yujie Dong of the Department of Ultrasound Medicine at the same institution, set out to fill that gap. The researchers first profiled ZNF143, a zinc finger transcription factor that binds specific GC-rich DNA motifs and acts both as an activator and repressor of transcription. ZNF143 is best studied in cancer biology, where it promotes glioma growth through KPNA2-mediated Hippo signalling and supports breast cancer cell survival through the NQO1–p53–Beclin1 axis under metabolic stress. Prior work by the same team had already implicated ZNF143 in fatty liver disease, showing that it inhibits hepatocyte mitophagy by upregulating the long non-coding RNA NEAT1 and activating the ROCK2 pathway. The current study extends that work by identifying an entirely separate, protein-level arm of the same transcription factor’s suppressive effect on mitochondrial quality control.

To test their hypothesis, the researchers used two complementary models of MASLD. The first was an in vivo model in which C57BL/6J mice were fed a high-fat diet for 16 weeks to induce hepatic steatosis and metabolic stress. The second was an in vitro model in which Huh-7 human hepatoma cells, a standard hepatic cell line, were exposed to free fatty acids to mimic lipid overload. Histological changes were assessed by hematoxylin and eosin staining, lipid accumulation was quantified by Oil Red O staining, and mitochondrial damage was assessed with JC-1 staining to monitor mitochondrial membrane potential and transmission electron microscopy to visualize mitochondrial ultrastructure. Serum and tissue markers of liver injury, including alanine aminotransferase, aspartate aminotransferase, total cholesterol and triglycerides, were measured to gauge the severity of hepatic dysfunction.

When the team examined the high-fat-diet-fed mice and the free-fatty-acid-treated Huh-7 cells, they found that ZNF143 was significantly upregulated in both settings, consistent with a role for this transcription factor in disease progression rather than simply a bystander effect. When the researchers knocked down ZNF143 using RNA interference, the consequences were striking: lipid accumulation in the liver decreased, mitochondrial damage was reduced, and liver injury markers fell. The mechanism behind this improvement was traced to a restoration of hepatocyte mitophagy, confirming that ZNF143 acts as a brake on mitochondrial quality control during MASLD.

The next step was to identify the transcriptional target through which ZNF143 exerts its effect. Using chromatin immunoprecipitation, the researchers demonstrated that ZNF143 binds directly to the promoter region of SMURF1, a HECT-type E3 ubiquitin ligase known for its role in ubiquitinating and degrading diverse substrate proteins in cancer, vascular remodeling and inflammatory signalling. Dual-luciferase reporter assays confirmed that this binding functionally activates SMURF1 transcription. In other words, ZNF143 does not merely correlate with MASLD; it actively turns up the expression of a ubiquitin ligase that then acts downstream.

SMURF1 has a complicated history in liver biology. Previous studies have shown that deleting Smurf1 attenuates liver steatosis in mice by stabilizing p53, and that Smurf1 aggravates fatty liver disease by stabilizing SREBP-1c, a master regulator of lipid synthesis, in an E3-activity-independent manner. Conversely, another study reported that SMAD-specific E3 ubiquitin protein ligase 1 can be protective in alcoholic steatohepatitis. The current study adds a new substrate to SMURF1’s growing portfolio in hepatic disease and clarifies how this E3 ligase suppresses mitochondrial quality control. Using co-immunoprecipitation, the team showed that SMURF1 physically interacts with TRPV1, the transient receptor potential vanilloid type 1 ion channel, and that SMURF1 ubiquitinates TRPV1, leading to its proteasomal degradation. TRPV1, the receptor activated by capsaicin, the pungent compound in chili peppers, has long been linked to metabolic health. Activation of TRPV1 by dietary capsaicin improves visceral fat remodelling through calcium influx, and TRPV1 activation prevents fatty liver disease in mice through upregulation of the mitochondrial uncoupling protein UCP2. By degrading TRPV1, SMURF1 removes a protective channel that supports mitochondrial and metabolic homeostasis in the hepatocyte.

The researchers then performed epistasis experiments to confirm the hierarchy of the pathway. When they knocked down TRPV1 in free-fatty-acid-treated Huh-7 cells that had already had ZNF143 depleted, the beneficial effect of ZNF143 knockdown on mitophagy was reversed. Similarly, overexpressing SMURF1 in ZNF143-depleted cells abolished the improvement in mitochondrial clearance. These results established that ZNF143 acts upstream of SMURF1 and TRPV1 in the same linear pathway: ZNF143 turns on SMURF1 transcription, SMURF1 ubiquitinates TRPV1 and targets it for degradation, and loss of TRPV1 suppresses mitophagy, leading to mitochondrial dysfunction and fat accumulation.

The significance of the finding is twofold. First, it adds to the emerging view that MASLD is fundamentally a disorder of impaired mitochondrial turnover, not simply one of excessive lipid synthesis. Multiple groups have shown that PINK1/Parkin-mediated mitophagy relieves fatty liver disease and that reversing Parkin-related mitophagy attenuates the condition. The current work identifies ZNF143 as a transcriptional switch that turns this quality control system off, providing a mechanistic explanation for why mitophagy declines during disease progression. Second, the study places TRPV1 — a channel best known from pain biology and dietary capsaicin research — at the centre of hepatic mitochondrial homeostasis. Recent work has implicated TRPV1 in mitophagy regulation in other contexts as well, including a 2025 report showing that TRPV1 inhibits both ferroptosis and mitophagy in heart failure through SFXN2, and a 2020 study showing that blocking TRPV1 promotes terminal mitophagy in multiple myeloma. The context-dependent role of TRPV1 in mitophagy across different tissues remains an open question, but the current study firmly establishes it as a downstream effector of ZNF143 in hepatocytes.

Therapeutically, the pathway offers several potential points of intervention. Small-molecule inhibitors of ZNF143 activity have already been developed for cancer applications, including YPC-21661 and YPC-22026, which were shown to inhibit ZNF143 activity both in vitro and in vivo. Inhibitors of SMURF1 have been designed for pulmonary arterial hypertension, suggesting that pharmacological tools against this E3 ligase could be repurposed for metabolic liver disease. Alternatively, TRPV1 agonists such as capsaicin or its analogues could theoretically compensate for the loss of TRPV1 protein caused by SMURF1-mediated degradation, consistent with epidemiological and experimental data suggesting that capsaicin may promote vascular and metabolic health. The authors note that the study’s findings, generated in mice and in a human hepatoma cell line, will need to be validated in human tissue samples and in additional model systems before any clinical translation.

The research was performed in accordance with guidelines approved by the Medical Ethics Committee of the First Affiliated Hospital of University of South China, and all authors declare no conflict of interest. The datasets generated and analysed during the study are available within the published article. As global rates of MASLD continue to climb in parallel with obesity and type 2 diabetes, identifying transcription factors such as ZNF143 that govern mitochondrial quality control provides a mechanistic framework for understanding disease progression and offers a roadmap for developing targeted therapies that restore the hepatocyte’s ability to clear its damaged mitochondria before steatosis spirals into inflammation, fibrosis and cancer.

The work matters because MASLD, which spans a spectrum from simple steatosis to inflammation, fibrosis, cirrhosis, and ultimately hepatocellular carcinoma, has no universally approved pharmacological therapy. Vitamin E has long been considered one of the few nutritional interventions with clinical evidence behind it, but most laboratory studies have relied on simplified single-cell cultures or animal models that poorly reflect human liver biology. The new study attempts to close that gap by building a model that incorporates both hepatocyte-like cells and hepatic stellate cells growing on a hydrogel derived from actual liver tissue.

The team, led by Seyedeh Kiana Teymoorian of the Royan Institute and the University of Science and Culture in Tehran, together with senior authors Massoud Vosough and Abbas Piryaei, constructed their model from two well-characterized human cell lines: Huh-7 hepatocyte-derived cells and LX-2 hepatic stellate cells, mixed at a ratio of four to one. This pairing is not arbitrary. In the living liver, hepatocytes store and metabolize fat, while stellate cells are the quiet fibroblasts that, when provoked by injury and inflammation, transdifferentiate into myofibroblast-like cells that produce collagen and drive fibrosis. Lipid overload in hepatocytes injures them, activates resident macrophages, and ultimately rouses the stellate cells into their fibrotic state, so a model that contains both cell types can capture at least one crucial axis of the disease that monocultures cannot.

What makes the platform distinctive is its substrate. The researchers coated the culture plates with LEMgel, a hydrogel prepared from decellularized sheep liver. To make it, they cut liver tissue into thin slices, stripped away all cellular material using detergents, freeze-dried the remaining scaffold, and dissolved it enzymatically in pepsin and acetic acid until a liquid at 10 milligrams per milliliter remained. Diluted to a coating concentration of 100 micrograms per milliliter, this preparation deposits a fibrous extracellular matrix, most likely rich in collagen, that provides both the structural texture and the biochemical signals of a real hepatic microenvironment. An MTS viability assay confirmed the coating was fully biocompatible, with no significant difference in cell survival between coated and uncoated plates.

With the stage set, the researchers induced disease by feeding the co-culture a fatty cocktail: 330 micromolar oleic acid and 165 micromolar palmitic acid, the two free fatty acids most abundant in the Western diet, delivered in complex with fatty acid-free bovine serum albumin. Two days of exposure produced robust and stable steatosis. Oil Red O staining, which dyes neutral triglycerides red, showed heavy intracellular lipid accumulation that persisted across six days of culture, and Nile Red fluorescence provided independent confirmation. Gene expression analysis sealed the diagnosis: carnitine palmitoyltransferase 1 (CPT-1), the rate-limiting transporter that shuttles long-chain fatty acids into mitochondria; SREBP-1c, the master transcription factor of de novo lipogenesis; and CD36, the fatty acid translocase on the cell surface, were all significantly upregulated compared with untreated controls. The co-culture was, in molecular terms, genuinely steatotic.

Then came the therapy. The team screened five doses of vitamin E, from 20 to 200 micromolar, and found that every dose reduced lipid accumulation, but concentrations of 100 micromolar and above cut it roughly in half compared with the fatty-acid-treated group. Because 100 micromolar achieved maximal benefit at the lowest effective concentration without any cytotoxicity, the researchers selected it for the full four-day treatment protocol. Cell viability, which had sagged under fatty acid exposure, rebounded significantly at every dose tested.

The molecular profile of the treated cells told a coherent story of recovery. Vitamin E downregulated CPT-1, NOX4, the NADPH oxidase enzyme that generates reactive oxygen species, along with SREBP-1c, CD36, and PPAR gamma, all drivers of lipid uptake and synthesis. Meanwhile it upregulated the antioxidant arm of the cellular defense: heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), two canonical downstream targets of the Nrf2 transcription factor, which functions as the master switch of the oxidative stress response. Superoxide dismutase and glutathione, two pillars of antioxidant chemistry, had both been depleted by fatty acid exposure; vitamin E restored glutathione levels significantly, although SOD secretion did not change measurably, suggesting the vitamin may act primarily through the glutathione system at this dose and duration.

The fibrosis axis of the model responded as well. Fatty acid treatment elevated ACTA-2, the gene encoding smooth muscle alpha actin, and COL1A1, the gene for type I collagen, both classic fingerprints of activated stellate cells. Vitamin E significantly reduced the expression of both. Consistent with this, transforming growth factor beta, the cytokine that activates LX-2 cells and propels fibrogenesis, rose sharply in the diseased model and fell dramatically after treatment. The researchers also tracked markers of hepatocyte maturity: albumin secretion, which had dropped under lipid stress, recovered with vitamin E, while alpha-fetoprotein, an indicator of immature or injured hepatocytes, had risen in the diseased state and fell to half its level after treatment.

At the protein level, Western blotting delivered perhaps the study’s most suggestive mechanistic finding. Both Nrf2 and CES1, a carboxylesterase that hydrolyzes triglycerides and cholesterol esters and sits downstream of Nrf2 signaling, were cut to roughly half their normal levels in the MASLD model. Vitamin E treatment restored both proteins to approximately control levels. Because CES1 governs the breakdown of stored fats, its suppression in fatty liver conditions directly promotes steatosis, and its recovery under vitamin E provides a plausible route by which the vitamin clears intracellular lipids. The authors are careful, however, not to overclaim: because they did not perform Nrf2 inhibition or knockdown experiments, they cannot conclude causally that all of vitamin E’s benefits flow through Nrf2, only that the pathway’s activation accompanied the therapeutic effects.

The physiological plausibility of the findings rests on well-established biochemistry. Vitamin E, a lipid-soluble antioxidant, intercalates into membranes where it neutralizes lipid radicals and interrupts the chain reaction of lipid peroxidation, a process central to the transition from simple steatosis to inflammatory steatohepatitis. Excess hepatic fat drives mitochondrial beta-oxidation into overdrive, flooding the cell with reactive oxygen species, overwhelming antioxidant defenses, stressing the endoplasmic reticulum, and pushing stellate cells toward fibrosis. By quenching radicals at their membrane source and simultaneously boosting Nrf2-driven enzymatic defenses, vitamin E attacks the vicious cycle at two points. The apparent reduction of CPT-1 expression after treatment, rather than an increase, the authors interpret as a sign that the compensatory stress response to lipid overload had subsided, an interpretation that reconciles their result with earlier mouse studies in which vitamin E raised CPT-1 while actively burning fat.

The study has honest limitations. The 2D co-culture omits Kupffer cells and other immune components that fuel inflammation in real livers, it relies on immortalized cell lines rather than primary human hepatocytes, and it lacks direct reactive oxygen species measurements. The authors suggest that future work with Nrf2 inhibitors, siRNA knockdown, primary cells, or organoid systems could firm up the mechanistic picture and extend the findings. Still, they position their platform as a pragmatic middle ground: far cheaper and faster than 3D organoids or animal studies, yet far more faithful to liver physiology than flat monocultures, because it combines cell-cell communication with tissue-derived extracellular matrix.

For a disease projected to become the leading indication for liver transplantation, and for which no drug has yet secured broad regulatory approval, accessible models that can rapidly screen candidate therapies are themselves a form of progress. The Tehran-Stockholm team’s platform, and the vitamin E data it generated, suggest that a humble vitamin, evaluated in a dish that looks and behaves a little more like a liver, can still teach the field something new.Subject of Research: Effects of vitamin E on oxidative stress, steatosis, and Nrf2 signaling in a biomimetic in vitro model of metabolic dysfunction-associated steatotic liver disease (MASLD)

The liver sits at the centre of this metabolic traffic system. It receives fatty acids released from adipose tissue, manufactures new fatty acids from excess nutrients, oxidizes lipids for energy and packages fats into lipoproteins for export. Under healthy conditions, these pathways are balanced. When the incoming and newly synthesized lipid supply exceeds the liver’s ability to burn or export it, triglycerides accumulate in hepatocytes. This is hepatic steatosis. The condition is not simply a passive storage problem: excess lipid can alter cellular signalling, promote oxidative stress and disturb the organ’s broader metabolic functions. In the context of obesity and insulin resistance, increased delivery of fatty acids to the liver can coincide with increased production of new fat, creating a biochemical surplus that is difficult to clear.

One major source of that surplus is de novo lipogenesis, the conversion of carbohydrates into fatty acids within the liver. When nutrient excess and metabolic dysfunction activate lipogenic programmes, the liver can manufacture more fat even when dietary fat intake is not the only or dominant source. At the same time, impaired fatty acid oxidation reduces the liver’s capacity to dismantle fatty acids in mitochondria and use them as fuel. The third pressure comes from lipoprotein biology. The liver normally assembles triglycerides and cholesterol into particles such as very-low-density lipoprotein, or VLDL, which transports lipids through the circulation. If lipid production, oxidation and export fall out of balance, fat remains trapped in the organ. The result is a metabolic traffic jam: more cargo arrives or is created, less is burned, and the exit routes become inadequate.

The relationship also runs in the opposite direction. A fatty liver can reshape the composition and flow of circulating lipids, contributing to the dyslipidaemic patterns associated with cardiovascular risk. Abnormal lipoprotein production and altered lipid handling can expose tissues to excess atherogenic particles, which may enter the arterial wall and help initiate or accelerate plaque formation. Dyslipidaemia and hepatic steatosis therefore reinforce one another rather than operating as isolated diagnoses. Their overlap is especially important in MASLD, the specific disease category in which liver fat accumulation is linked to metabolic dysfunction. The condition is now recognized as a major manifestation of systemic metabolic disease, not merely an incidental imaging finding. This shared biology explains why strategies capable of reducing both hepatic and plasma lipid burdens could have effects extending beyond a single organ.

The therapeutic problem becomes sharper when the mechanism of a lipid-lowering drug is considered. Some treatments reduce circulating lipids by limiting the liver’s production or secretion of lipoproteins. That approach can lower the amount of lipid released into the blood, but it may also reduce the liver’s ability to export its own lipid cargo. If lipoprotein production is suppressed without a matching improvement in lipid breakdown or another route of disposal, hepatic fat may accumulate. The review emphasizes that such therapies may therefore require careful monitoring of hepatic lipid content. This does not mean that lipid-lowering treatment is inherently harmful to the liver, nor that patients should alter therapy without medical supervision. It means that the same pathway can produce different consequences in different compartments: less lipid in plasma may coexist with more lipid inside hepatocytes.

A contrasting strategy acts through the LDL receptor, a protein on the surface of liver cells that captures low-density lipoprotein particles from the bloodstream. Increasing hepatic LDL-receptor expression accelerates the removal of LDL from circulation and generally lowers plasma LDL cholesterol without forcing the liver to reduce lipoprotein export in the same way. According to the review, drugs that lower blood lipids through this receptor-driven clearance pathway do not lead to lipid accumulation in the liver. Yet the response is not uniform. Some patients are less responsive than others, reflecting biological differences in receptor regulation, lipoprotein metabolism and the wider metabolic environment. This variation is one reason why cardiovascular prevention cannot depend on a single universal mechanism. It also highlights the need to understand not only whether a drug lowers a laboratory value, but how it changes the movement and storage of lipid throughout the body.

The next generation of therapies may need to solve a more intricate engineering problem: lowering atherogenic lipoproteins while preserving, or even improving, the liver’s ability to maintain lipid balance. The review calls for treatments that decrease lipoprotein production without causing steatosis, a goal that may require carefully calibrated rather than simply maximal suppression of hepatic output. Balanced modulation could involve coordinating lipoprotein synthesis and secretion with systemic lipid catabolism, the cellular processes that break down and recycle lipids. At the cellular level, this means accounting for the fate of fatty acids, triglycerides and cholesterol together rather than targeting one circulating measurement in isolation. A drug that changes one node in the network can redirect metabolic flux through another, potentially creating benefits in the bloodstream but unintended pressure inside the liver.

This systems-level view could change how clinicians and researchers evaluate lipid-lowering medicines. Blood tests remain essential, particularly measurements of LDL cholesterol and other atherogenic lipoproteins, but they may not capture every relevant consequence of altered hepatic metabolism. Assessing liver fat and function becomes especially important when a treatment interferes with lipoprotein biosynthesis or secretion. Conversely, a therapy that promotes hepatic clearance of circulating LDL may reduce cardiovascular exposure without producing the same steatotic liability. The distinction is mechanistic rather than cosmetic: two drugs can lower plasma lipid concentrations while producing different intracellular effects because they alter different pathways. Understanding those pathways may help explain variable treatment responses and support more individualized approaches for people who have both dyslipidaemia and MASLD.

The review also points toward a broader reframing of cardiovascular prevention. Atherosclerosis develops in the arterial wall, but its fuel supply is shaped by organs and tissues that regulate lipid production, storage, transport and removal. The liver is the main processing hub in this network, making it a natural target for therapies designed to reduce vascular risk. At the same time, liver safety cannot be separated from therapeutic success when metabolic disease is widespread. Obesity and diabetes can amplify lipid imbalance, increase fatty-acid delivery to the liver and make the consequences of altered lipoprotein handling more pronounced. Treatments that address only plasma lipids may leave hepatic disease untouched, while approaches that focus only on liver fat may fail to reduce the atherogenic particles responsible for vascular injury. The most powerful interventions may therefore be those that act on both sides of the connection.

The emerging message is not that lipid lowering has reached a dead end, but that the field is moving beyond a one-number definition of success. The future of therapy will depend on controlling where lipids go, how quickly they are made, how efficiently they are burned and through which routes they leave the liver. By mapping the mechanistic links between dyslipidaemia and hepatic steatosis, the authors identify a therapeutic balancing act with unusually high stakes: reduce harmful lipid exposure in the circulation without converting the liver into a storage depot. Strategies that coordinate plasma lipid reduction with hepatic lipid homeostasis could ultimately lower the burden of both atherosclerosis and MASLD. In a world where cardiovascular and metabolic liver disease increasingly overlap, the winning treatments may be those that make the entire lipid-handling system work better—not merely those that make one blood test look better.

LCA is a secondary bile acid produced when intestinal microorganisms transform primary bile acids. It participates in bile acid metabolism and can influence cellular signaling, energy balance, and inflammation. At high concentrations, however, LCA has been linked to cholestasis, impaired bile flow, obstruction of bile ducts, hepatocyte injury, and cell death. This apparent contradiction has complicated efforts to explore LCA as a possible therapy. Earlier work had shown that LCA levels rise during caloric restriction, a dietary intervention associated with longer lifespan and improved metabolic health in several organisms.

Caloric restriction is thought to activate a network of metabolic responses that improve glucose handling, mitochondrial function, stress resistance, and tissue maintenance. LCA has been proposed as one of the circulating molecules that may help transmit some of these benefits. In animal studies, the bile acid has been associated with increased muscle NAD+ levels, improved grip strength and endurance in aged mice, and longer lifespan in nematodes and fruit flies. Yet the doses required to produce such effects must be distinguished from the much higher exposures known to damage the liver.

To investigate this dose boundary, a team led by Sheng-Cai Lin of Henan University and Xiamen University first studied obese mice. The animals received LCA in their drinking water at a concentration of 1 gram per liter, producing blood levels of approximately 1 micromole per liter. That exposure was designed to resemble the concentration observed during caloric restriction rather than the substantially higher levels used in toxicology experiments. After four weeks, the mice had lower hepatic triglyceride content, reduced fatty liver, and improved glucose metabolism.

The researchers also examined the molecular pathway behind the response. Liver-specific knockout mice lacking AMPKα did not receive the same metabolic benefits, implicating AMP-activated protein kinase as a central mediator. AMPK is an energy-sensing enzyme that becomes active when cellular energy supplies are limited. Once activated, it can suppress energy-intensive processes such as lipid synthesis while promoting fatty-acid oxidation and other pathways that help restore energy balance. The results indicate that low-dose LCA may improve liver metabolism through this energy-sensing system.

The safety picture changed sharply when the dose was increased. At 250 milligrams per kilogram per day, hepatic LCA concentrations reached about 14 micromoles per liter, and the mice developed clear signs of liver injury. This contrast provided direct evidence for a dose-dependent safety window: concentrations near those associated with caloric restriction appeared beneficial, while substantially higher exposure became toxic. The distinction is particularly important because bile acids can accumulate in the liver and exert effects that are not predicted simply by the administered dose.

The team next tested LCA in cynomolgus macaques with fatty liver. Translating doses from rodents to primates proved more complicated than expected. The monkeys rejected the formulation used in the mouse experiments, so the researchers developed a phospholipid-coated preparation suspended in fish oil. When they administered a mouse-equivalent dose calculated by body-surface-area conversion—9.6 milligrams per kilogram—the animals’ serum LCA concentrations rose above 6 micromoles per liter. Within one week, alanine aminotransferase and aspartate aminotransferase, enzymes commonly used to detect liver injury, increased significantly.

That result demonstrated why standard interspecies dose conversion can be unreliable for compounds whose absorption, metabolism, and circulation differ between animals. The researchers therefore conducted a dose-titration study in the macaques and identified two lower regimens: 0.25 milligrams per kilogram and 0.5 milligrams per kilogram, administered twice daily. These schedules maintained steady-state blood concentrations of approximately 0.8 to 1 micromole per liter, close to the target range observed in the mouse experiments, without producing biochemical evidence of liver damage.

After 13 weeks, macaques receiving either low-dose regimen showed significant histological improvement in hepatic steatosis, the abnormal accumulation of fat inside liver cells. Their body weight, blood lipids, and glucose levels remained stable, while ALT, AST, creatinine, and blood counts showed no treatment-related abnormalities. The findings do not establish that LCA is ready for human use, and the study involved early-stage fatty liver rather than advanced disease with severe hyperglycemia or hypertriglyceridemia. Longer studies will be needed to assess tissue distribution, sex-related differences, chronic toxicity, and responses in more advanced models. Nevertheless, the work provides the first reported evidence in a non-human primate that a carefully controlled, caloric-restriction-like concentration of LCA may alleviate fatty liver through hepatic AMPK activation without detectable toxicity.

Article Title: Lithocholic acid alleviates fatty liver in mice and non-human primate macaques

News Publication Date: 23-Jul-2026

Web References: https://doi.org/10.1093/lifemeta/loag023

References: Life Metabolism, DOI: 10.1093/lifemeta/loag023

Image Credits: Higher Education Press

Keywords: lithocholic acid, LCA, fatty liver, metabolic dysfunction-associated steatotic liver disease, caloric restriction, AMPK, bile acids, cynomolgus macaques, liver metabolism, hepatotoxicity

Central to this discovery is the enzyme valosin-containing protein (VCP), an essential molecular machine that orchestrates protein recycling within cells. Under normal physiological conditions, VCP ensures cellular homeostasis by identifying and removing proteins that have become dysfunctional or superfluous. Hepatocytes rely heavily on this system to manage lipid droplets—spherical fat storage organelles that serve as crucial energy reserves during metabolic stress such as fasting. However, when lipid droplets accumulate excessively, a pathological state known as hepatic steatosis or fatty liver ensues, severely impairing liver function.

The research, meticulously led by Dr. Mark McNiven and his team, uncovering VCP’s unanticipated role in regulating a specific protein named HSD17β13, provides substantial insights. HSD17β13 anchors on the surface of lipid droplets, and in healthy liver cells, its levels are tightly controlled by VCP-mediated degradation pathways. It was startling to observe that VCP directly engages with HSD17β13, removing it from lipid droplets and ferrying it to the lysosome, an intracellular organelle responsible for breaking down unwanted protein aggregates. This surveillance mechanism curtails the unchecked expansion of lipid droplets, maintaining cellular lipid equilibrium.

However, exposure to excessive ethanol—the active ingredient in alcoholic beverages—severely impairs this protective mechanism. The study reveals that alcohol effectively dislodges VCP from the lipid droplet surface, nearly eradicating its presence and thus incapacitating its regulatory duties. This loss precipitates an abnormal buildup of HSD17β13 on lipid droplets, triggering an increase in fat storage within hepatocytes. As lipid droplets balloon in size and number due to this protein accumulation, the liver’s architecture and function begin to deteriorate, setting the stage for fatty liver disease progression.

What makes these findings particularly compelling are the live cellular imaging experiments that captured VCP’s recycling choreography in unprecedented detail. The researchers visualized VCP in collaboration with chaperone proteins shepherding HSD17β13-laden lipid droplets towards the lysosome for degradation. This dynamic interplay underscores a finely tuned homeostatic circuit vulnerable to disruption by alcohol metabolites. The research team’s corroborative experiments unambiguously demonstrated that ethanol exposure cripples this cellular quality control system, shedding light on the molecular vulnerability that predisposes certain individuals to alcohol-associated liver damage.

This pivotal insight holds transformative implications not only for understanding disease etiology but also for therapeutic innovation. By identifying HSD17β13 as a potential drug target, the study lays the foundation for novel interventions aimed at modulating lipid droplet dynamics and preventing or reversing steatosis. Targeted therapies could conceivably restore or mimic VCP’s function, reestablishing the lysosomal degradation of excess HSD17β13 and arresting fatty liver disease at its nascent stage.

Moreover, these findings enrich the broader scientific narrative surrounding lipid biology and hepatocyte physiology. Lipid droplets have often been viewed merely as inert fat repositories, yet this research vividly illustrates their complex regulation and critical contribution to cellular health. It also highlights the liver’s remarkable capacity for protein quality control and adaptation—a capacity compromised by external toxins such as alcohol, with profound pathological consequences.

Additional relevance emerges from the study’s contribution to predictive medicine. Understanding how the VCP-HSD17β13 axis operates enables clinicians to potentially identify patients whose cellular systems are compromised, rendering them more susceptible to alcohol’s deleterious effects. This paves the way for personalized risk assessments and preemptive interventions, consistent with Mayo Clinic’s larger Precure initiative, which aims to intercept disease progression through early molecular detection and targeted therapeutics.

The rigorous investigation, published in the Journal of Cell Biology, exemplifies modern molecular biology’s power to unravel the interplay between lifestyle factors and cellular machinery. It also accentuates the importance of interdisciplinary research bridging biochemistry, cell biology, and clinical medicine to confront pervasive health challenges like fatty liver disease. As alcohol consumption remains widespread globally, these mechanistic insights are critical for public health strategies seeking to mitigate chronic liver conditions.

In conclusion, the elucidation of ethanol’s disruption of VCP-mediated protein recycling introduces a vital piece to the puzzle of fatty liver pathogenesis. By linking alcohol abuse directly to the malfunction of hepatocellular protein quality control systems, this study offers a clarion call for intensified research into molecular therapies. The seamless convergence of cutting-edge cell biology techniques and clinical insight promises not only enhanced disease comprehension but also innovative pathways towards effective prevention and treatment.

Subject of Research: Mechanistic insights into alcoholic fatty liver disease via disruption of VCP-mediated lipid droplet protein recycling.

Article Title: An ethanol-induced loss of the lipid droplet–associated segregase VCP/p97 leads to hepatic steatosis

News Publication Date: 29-Jul-2025

Web References:
https://rupress.org/jcb/article/224/8/e202408205/278160/An-ethanol-induced-loss-of-the-lipid-droplet
https://rupress.org/jcb/article/224/8/e202506103/278158/New-insights-into-lipid-droplet-breakdown-in?searchresult=1

References:
Detailed within the original Journal of Cell Biology publication.

Keywords: fatty liver disease, alcoholic liver disease, valosin-containing protein, VCP, lipid droplets, HSD17β13, ethanol toxicity, hepatocyte biology, protein recycling, lysosome, metabolic dysfunction, hepatic steatosis

This ground-breaking research centers on the metabolic enzyme ATP citrate lyase (ACLY), a key catalyst in the biochemical conversion of glucose to lipid molecules within liver cells. Tumor cells notoriously hijack this metabolic pathway, exploiting fat synthesis to fuel their unchecked growth and survival. The team at McMaster engineered a pharmacological agent — EVT0185 — designed to selectively inhibit ACLY activity within hepatic tissues. This targeted approach interrupts the tumor’s metabolic lifeline, substantially stunting its progression while sparing other organs from systemic side effects.

Strikingly, the treatment did more than halt tumor growth; it revitalized the immune environment within the liver. Conventional cancer immunotherapy paradigms emphasize the pivotal role of cytotoxic T lymphocytes (CTLs) in recognizing and eradicating cancer cells. However, the McMaster study revealed a surprising actor in the anti-tumoral immune orchestra: B cells. These antibody-producing lymphocytes, long overshadowed by T cells in cancer research, emerged as critical mediators of tumor clearance following ACLY inhibition.

The enhanced immunogenicity of liver tumors post-treatment was unexpected and profound. B cells infiltrated the tumor microenvironment in greater numbers, orchestrating complex immune responses that synergized with other immune components. This novel insight challenges the prevailing dogma that T cells are the sole immune warriors in solid tumors and suggests that modulating cancer metabolism can selectively amplify anti-tumor B cell activity.

At a mechanistic level, ACLY inhibition curtails the intracellular synthesis of acetyl-CoA derived from citrate, disrupting lipid biogenesis critical for membrane formation and energy storage in tumor cells. This lipid deprivation likely induces metabolic stress, exposing tumor-associated antigens and rendering cancer cells more visible to immune surveillance. Additionally, altering tumor metabolism may reshape cytokine profiles in the microenvironment, thereby recruiting and activating B cells more effectively.

Fatty liver disease, medically termed metabolic dysfunction–associated steatotic liver disease (MASLD), affects nearly eight million individuals in Canada alone, with a significant subset progressing to a more severe inflammatory state known as metabolic dysfunction-associated steatohepatitis (MASH). These patients bear a disproportionately high risk of developing aggressive liver cancers such as HCC, which historically has seen dismal survival rates—less than 20% of patients survive beyond five years. The introduction of EVT0185 and its ACLY-targeted mechanism offers a promising avenue to alter this grim prognosis.

In preclinical trials, murine models simulating human MASH coupled with HCC were treated with EVT0185, resulting in a marked reduction in both tumor burden and growth rate. Importantly, treated tumors exhibited heightened susceptibility to immune-mediated destruction, primarily through B cell engagement rather than the anticipated cytotoxic T cell pathways. This discovery opens new investigative directions into B cell biology within cancer and may inspire innovative immunotherapies designed to harness these cells’ full potential.

While promising, the research team acknowledges the complexity inherent in translating these findings to clinical practice. Future studies must unravel the precise immunological cascades initiated by ACLY inhibition, determine the safety and efficacy of EVT0185 in human subjects, and explore whether similar strategies can be effective across diverse malignancies with metabolic dependencies. Moreover, understanding how B cells communicate with other immune subsets in the tumor microenvironment will be crucial in designing comprehensive treatment protocols.

This investigation exemplifies the power of targeting cancer metabolism not merely as a metabolic reprogramming stance but as a strategic lever to remodel immune responses. By switching off a vital metabolic enzyme, researchers have demonstrated a capacity to “unmask” tumors and enlist underappreciated immune players in the eradication effort, thereby expanding the therapeutic landscape beyond conventional cytotoxic and checkpoint inhibitor approaches.

The study was made possible through funding from the Canadian Institutes of Health Research Foundation Grant and collaborative investment from Espervita Therapeutics, underscoring the increasing importance of academia-industry partnerships in advancing translational medicine. Notably, several authors maintain shareholder positions within Espervita, highlighting a close integration of research innovation and biotechnological development.

As this research paves the way for next-generation liver cancer therapies, it also sparks a broader imperative to revisit the metabolic underpinnings across other cancers. Metabolic enzymes like ACLY may constitute a new class of druggable targets capable of simultaneously disabling tumor nutrition and invigorating immune defenses. Such dual-action therapeutics could revolutionize oncological treatment paradigms, addressing resistance mechanisms and poor immunogenicity that have long hampered success.

In summary, the McMaster University and Espervita Therapeutics collaboration reveals a transformative approach to liver cancer treatment by inhibiting ACLY, the pivotal enzyme linking carbohydrate metabolism to fat synthesis. This intervention disrupts tumor metabolic homeostasis, triggers an unexpected B cell-driven immune response, and reduces tumor viability in preclinical models. While human trials are the next critical step, these findings significantly deepen our understanding of cancer immunometabolism and open promising avenues for combating one of the world’s deadliest cancers.

Subject of Research: Liver cancer metabolism and immune system interaction focusing on ACLY enzyme inhibition and B cell-mediated tumor immunity
Article Title: Inhibiting ACLY enhances tumour immunogenicity and resolves MASH-HCC
News Publication Date: 30-Jul-2025
Web References: 10.1038/s41586-025-09297-0
Keywords: Cancer, Liver cancer, Metabolism, Immunotherapy, B cells, ATP citrate lyase, Fatty liver disease, MASLD, MASH, Tumor microenvironment, Hepatocellular carcinoma, Immune metabolism